Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.
- India’s Service Sector Ends on a Strong Note
- DPIIT Joins Hand with Stride Ventures to Support Indian Startups
- Anarock to Increase Office Leasing Team to Cater to Rising Demand
- NTPC Green Shares Soar 3% on Securing 1,000 MW Power Project
- Brigade Enterprises Shares Gain 1% on Acquiring Land Parcel in Bengaluru
The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.
